E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Relapsed glioblastoma multiforme |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10018337 |
E.1.2 | Term | Glioblastoma multiforme |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Determine the efficacy of this regime, in terms of objective tumour response rate (complete response and partial response) in these patients |
|
E.2.2 | Secondary objectives of the trial |
1. Determine the clinical benefit rate (CR+PR+SD). 2. Determine the progression- free survival in patients with recurrent glioblastoma multiforme treated with BIBF 1120. 3. Describe the adverse event profile of this regimen in these patients. 3. Compare pre-vs-post treatment measurements of biomarkers and vascular system/immune system parameters in patients treated wit this regimen. 4. Correlate tumor and blood biomarkers with clinical response in these patients (VEGF, VEGFR1,VEGFR2,Ca-9,TIMP-1,) Blood (validated assays): PIGF, sVEGFR2, bFGF, UPA, UPAR cleavage
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Written informed consent Histological verification of primary GBM and failure after radiotherapy and TMZ - Previously received radiotherapy and TMZ More than 4 weeks since any of the following prior treatments - Chemotherapy (6 weeks for nitrosureas or mitomycin C) - Radiotherapy to nontarget lesions or lesions that are not to be biopsied - Investigational agents More than 6 months since prior major surgery or open biopsy and recovered (only 6 weeks required if operation is for recurrent BGM) ● ECOG performance status 0-1 Age > 18 years Creatinine normal OR creatinine clearance ≥ 60 mL/min Fertile females must use anticonception (p- pills, IUD, depot injection of gestagen, subdermal implantation, hormonal vaginal ring or transdermal depot plaster, througout the study and 3 months efter discontinuation of study drugs. Fertile men must use dobbelt barrier method (preservative with sperm inhibiting creme) or female partner uses the above mentioned contraception. Fertile males must use preservatives.
|
|
E.4 | Principal exclusion criteria |
Prior treatment with BIBF 1120 or any other VEGFR inhibitor, except bevacizumab in Group 2 Chemo-, hormono-, radio-(except for brain and extremities) or immunotherapy or therapy with monoclonal antibodies or small tyrosine kinase inhibitors within the past 4 weeks prior to treatment with the trial drug. Persistence of clinically relevant therapy related toxicity from previous chemo and/or radiotherapy Treatment with other investigational drugs or treatment in another clinical trial within the past 4 weeks before start of therapy or concomitantly with the trial Therapeutic anticoagulation( except low-dose heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous devise) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic acid<325mg per day Major injuries within the past 10 days prior to start of study treatment with incomplete wound healing and/or planned surgery during the on-treatment study period History of clinically significant haemorrhagic or thromboembolic event in the past 6 months Known inheritated predisposition to bleeding or thrombosis Significant cardiovascular diseases ( i.e. uncontrolled hypertension, unstable angina, history of infarction within the past 12 months prior to start of study treatment, congestive heart failure > NYHA II, serious cardiac arrhythmia, pericardial effusion) Proteinuria CTCAE grade 2 or greater Hepatic function: total bilirubin outside of normal limits; ALT or AST > 1.5 ULN Coagulation parameters: International normalised ratio ( INR) > 2, prothrombin time - (PT) and partial thromboplastin time (PTT) > 50% of deviation of institutional ULN Absolute neutrophil count ( ANC) < 1500/ml, platelets < 100000/ml, Haemoglobin < 9.0 g/dl Other malignancies within the past 5 years other then basal cell skin cancer or carcinoma in situ of the cervix Active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy Active or chronic hepatitis C and/or B infection Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug Serious illness or concomitant non-oncological disease such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with study participation or study drug administration and in the judgment of the investigator would make the patient inappropriate for entry into the study. Pregnancy or breast feeding Psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule active alcohol or drug abuse
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visi of last subject |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |